JBA: Setsuo Morishita on the History of JBA, and Biotechnology in Japan




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: JBA: Setsuo Morishita on the History of JBA, and Biotechnology in Japan
Released on: November 17, 2010. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, Fintan Walton talks to Setsuo Morishita, Deputy Director of Japan Bioindustry Association, about the History of JBA. They discuss:

• Growth of Biotechnology in Japan over the last decade

• Future of biotech in Japan
History of JBA
Fintan Walton:
Hello and welcome to PharmaTelevision News Review here at the Japan Biotech Forum in London. On this show I have Setsuo Morishita, who is a Deputy Director of the Japan Bioindustry Association , welcome to the show.
Setsuo Morishita:
Thank you.
Fintan Walton:
Setsuo Morishita you are the Deputy Director of a very important industry association in Japan, could you tell us the history of the Japan Bioindustry Association ?
Setsuo Morishita:
Bioindustry Association in Japan has a long history back to World War II. The first organization was found in 1942 and during World War II Japan didn't have a energy oil so you know the organization tried to make alcohol as energy by fermentation technology and after the war the organization was called Japan Society of Industrial Fermentation, around 20 years ago that organization has been reformed to Japan Bioindustry Association and get to cover not only fermentation but also the whole biotech biotechnology industry.
Fintan Walton:
Today how many members are there to the Japan Bioindustry Association ?
Setsuo Morishita:
Big companies about 200 including pharmaceutical, and chemical, and engineering companies.
Growth of Biotechnology in Japan over the last decade
Fintan Walton:
So the last 10 years it has been the emergence of biotechnology companies or bio venture backed companies and tell us what's happened in the last 10 years, how has the last 10-years has been for biotechnology and particularly amongst the smaller companies in Japan?
Setsuo Morishita:
In later 1990's we had some systemic change around financial sectors and academia including national universities there new companies emerged, I mean that the companies managed by this money from venture capitals and the technologies from universities and from 2000 to 2006 the emerging companies the number of emerging companies have increased significantly and financial status was very good, but after that recently the venture capitals shifted into low gear.
Future of biotech in Japan
Fintan Walton:
Did you still see a new better future for biotech in Japan?
Setsuo Morishita:
Last decade where we the smaller companies have some mistakes of the about their business brand and strategies of intellectual properties, but now the human resources of management growing up so that's promising I feel.
Fintan Walton:
Setsuo Morishita, thank you very much indeed for coming on the show. Thank you.
Setsuo Morishita:
Thank you very much.
Fintan Walton
Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).
Setsuo Morishita
Deputy Director
Setsuo Morishita , Deputy Director, Strategic Planning, Japan Bioindustry Association (JBA).
PharmaVentures
PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.
JBA
The JBA is a non-profit organization dedicated to the promotion of bioscience, biotechnology and bioindustry in both Japan and the rest of the world. Established through the support and cooperation of industry, academia, and government, JBA is the only organization of its kind in Japan. JBA's roots date back more than 50 years to the establishment of the Japanese Association of Industrial Fermentation. Today, like its predecessor organization, the JBA functions as a think tank and platform for communication between scientists, technologist, policymakers and managers.